Effect of short-term aspirin use on C-reactive protein.
Markers of inflammation, such as C-reactive protein (CRP) and fibrinogen, have been shown to be predictive of cardiovascular disease. In the Physicians Health Study, the magnitude of reduction in the risk of myocardial infarction with aspirin therapy was related to baseline CRP levels, raising the possibility that the protective effect of aspirin may be due to antiinflammatory properties in addition to its antiplatelet effect. We therefore investigated whether aspirin therapy lowers CRP levels. Because heavy physical exertion is a well-known trigger of myocardial infarction, we also investigated the effect of aspirin on CRP levels before and after strenuous exercise. Thirty-two healthy men, aged 29 +/- 6 years, were enrolled in a randomized, double-blind, parallel study. Blood samples were obtained immediately before and after maximal treadmill exercise at baseline and following 7 days of aspirin therapy (81 or 325 mg). The levels of CRP, as measured by ELISA, increased by 13% following exercise (P < 0.0001). However, aspirin did not significantly alter CRP levels, either at rest (0.81 +/- 0.13 mg/L before aspirin vs. 0.78 +/- 0.13 mg/L on aspirin) or following exercise (0.92 +/- 0.13 mg/L before aspirin vs. 0.86 +/- 0. 13 mg/L on aspirin), P = 0.73. When the resting and postexercise data were combined, the levels were 0.87 +/- 0.13 mg/L before aspirin and 0.82 +/- 0.13 mg/L on aspirin (a nonsignificant 6% reduction, P = 0.20). In conclusion, in healthy male subjects CRP levels were not significantly reduced by short-term aspirin therapy. Our data, taking together with other reports, suggest that aspirin may not affect the levels of inflammatory markers. However, further studies are needed with a longer duration of therapy, among subjects with coronary heart disease, and using additional markers of inflammation besides CRP to determine the long-term effects of aspirin use.
Feng
D
D
Institute for Prevention of Cardiovascular Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
Tracy
R P
RP
Lipinska
I
I
Murillo
J
J
McKenna
C
C
Tofler
G H
GH
D000209:Acute-Phase Proteins / Q000187:drug effects; D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D002097:C-Reactive Protein / Q000187:drug effects* / Q000378:metabolism; D004311:Double-Blind Method; D015444:Exercise; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000209:etiology / Q000378:metabolism; D009961:Orosomucoid / Q000187:drug effects; D013997:Time Factors
D000209:Acute-Phase Proteins; D009961:Orosomucoid; D002097:C-Reactive Protein; D001241:Aspirin